Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573216 | 0.94 | PDPK1 (0.42) | CSF1RNTRK1NTRK3NTRK2NPC1 | |
| SCHEMBL4758319 | 0.94 | PDPK1 (0.42) | CSF1RNTRK1NTRK3NTRK2NPC1 | |
| SCHEMBL3569691 | 0.94 | CSF1R (0.49) | CSF1RNTRK1NTRK3NTRK2NPC1 | |
| SCHEMBL3583080 | 0.92 | CSF1R (0.47) | CSF1RNTRK1NTRK3NTRK2NPC1 | |
| SCHEMBL3578295 | 0.90 | CSF1R (0.47) | CSF1RRAB9ASMN1; SMN2MAPT | |
| SCHEMBL3569694 | 0.89 | CSF1R (0.49) | CSF1RNTRK1NTRK3NTRK2NPC1 | |
| SCHEMBL3573384 | 0.89 | CSF1R (0.49) | CSF1RNTRK1NTRK3NTRK2NPC1 | |
| SCHEMBL3573380 | 0.89 | CSF1R (0.49) | CSF1RNTRK1NTRK3NTRK2NPC1 | |
| SCHEMBL3575773 | 0.89 | NTRK1 (0.45) | CSF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL3576911 | 0.88 | CSF1R (0.47) | CSF1RNTRK1NTRK3NTRK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | claimed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20080118538-A1 | OIL DISPERSION OF POWDER BEING SURFACE-TREATED WITH SPECIFIC HALF ESTER OIL, AND COSMETIC COMPOSITION CONTAINING THE SAME | MIYOSHI KASEI, INC. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| EP-1881039-A1 | OIL DISPERSION OF POWDER BEING SURFACE-TREATED WITH SPECIFIC ACIDIC ESTER OIL, AND COSMETIC COMPOSITION CONTAINING THE SAME | Miyoshi Kasei, Inc. (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | CSF1R 776/4885NTRK1 307/4885NTRK3 444/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | CSF1R 877/4885NTRK1 413/4885NTRK3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.